Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
2024年8月1日 - 9:30PM
Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered
into an agreement with Emory University, which will allow the
parties to evaluate and explore the potential for a future
collaboration in connection with autonomous robotics in
endovascular procedures. Under the terms of the agreement, Emory
University will assume the responsibility of exploring the
feasibility of integrating the LIBERTY® Endovascular Robotic
Surgical System with an imaging system to create an autonomous
robotic system for endovascular procedures. Amir Pourmorteza, PhD,
Assistant Professor in the Department of Radiology and Imaging
Sciences at Emory University Winship Cancer Institute, and
Department of Biomedical Engineering at Georgia Institute of
Technology, will lead the evaluation under Project Trita.
“Autonomous robotics has the potential to standardize outcomes,
improve efficiencies, reduce radiation exposure, and democratize
access to top-level healthcare,” commented Dr. Pourmorteza.
“Project Trita merges CT-guidance, artificial intelligence, and
medical Robotics. I am excited to work with Microbot Medical on
this project.”
“Our vision for the future of endovascular robotics includes
autonomous capabilities, which has the potential to standardize
endovascular procedures and improve access to benefit millions of
patients globally. We believe LIBERTY® can be integrated with
imaging, planning and navigation software to ultimately create an
autonomous robotic system that can be used in endovascular
procedures,” said Harel Gadot, CEO, President and Chairman of
Microbot Medical. “We’re excited to work with Dr. Pourmorteza who
is a leader in this space and we believe he shares a similar
vision.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
clinical- stage medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The Investigational LIBERTY® Endovascular
Robotic Surgical System aims to improve the way surgical robotics
are being used in endovascular procedures today, by eliminating the
need for large, cumbersome, and expensive capital equipment, while
reducing radiation exposure and physician strain. The Company
believes the LIBERTY® Endovascular Robotic Surgical System’s remote
operation has the potential to be the first system to democratize
endovascular interventional procedures.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of the
LIBERTY® Endovascular Robotic Surgical System, the outcome of its
studies to evaluate the LIBERTY® Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, including
whether the Company’s pivotal study in humans is successful, any
failure or inability to recruit physicians and clinicians to serve
as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians and
other neighboring countries, any lingering uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty
IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 8 2024 まで 9 2024
Microbot Medical (NASDAQ:MBOT)
過去 株価チャート
から 9 2023 まで 9 2024